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ABSTRACT 
 
Background: Although much research has examined the relationship between lifestyle and 
prostate cancer (PCa) risk, few studies focus on the relationship between lifestyle and PCa 
progression. The present study examines this among men initially diagnosed with low- to 
intermediate-risk PCa and managed with active surveillance (AS).  
Methods: Men enrolled in two separate AS programs were recruited for this study. Data 
regarding clinical, demographic and lifestyle characteristics were collected. Results were 
then compared between men whose disease remained low- to intermediate-risk and men 
whose disease progressed. 
Results: Demographic, clinical and physical characteristics were similar between 
comparative groups and cohorts; with the exception that age at the time of diagnosis and 
questionnaire was increased among men whose disease progressed. Lifestyle scores among 
men who remained low to intermediate risk were higher than those who progressed; 
however, scores were only significant in one cohort upon univariable analysis. Upon 
multivariable analysis, the only predictor of progression was age at diagnosis. Physical 
activity was consistently higher in both low-risk groups, though this difference was 
insignificant. Consistent differences in other lifestyle variables were not observed.  
Conclusions: Age remains an important predictor of PCa progression. Improving lifestyle 
characteristics among men initially managed with active surveillance might help to reduce 
the risk of progression. Given the limitations of this study, more rigorous investigation is 
required to confirm whether lifestyle characteristics influence the progression of low- to 
intermediate-risk PCa. 
Introduction 
 
 With the introduction of PSA testing, the incidence of prostate cancer (PCa) has 
risen dramatically and is now the second-most frequently diagnosed cancer in the world 
[1]. While therapies such as surgery or radiation provide significant survival benefits for 
aggressive PCa, treatment for low risk disease can cause considerable morbidity and risk, 
unnecessarily [2, 3]. Low risk PCa typically progresses very slowly, and delaying treatment 
until signs of higher risk disease has not shown to decrease the likelihood of successful 
treatment [2, 4]. As such, active surveillance (AS), in which treatment is initially deferred, 
has become a sensible option for such patients [5].  
 While much research has examined the relationship between lifestyle and PCa risk, 
very few studies have focused on the effect of lifestyle on PCa progression. AS programs 
provide excellent opportunities to assess the impact of lifestyle on PCa progression without 
any confounding treatment effects. Although to date this potential has not been well 
realized, there is some indication that a healthy lifestyle, including physical activity, may 
delay the need for radical treatment in men on AS [6-8].  
In the present study, we examined the association between lifestyle characteristics 
and disease progression in men diagnosed with low- to intermediate-risk PCa and initially 
managed with AS. The study consists of men from Sunnybrook Health Sciences Centre AS 
cohort (SB cohort) and the Institute of Cancer Research, Royal Marsden Hospital AS cohort 
(RMH cohort). It was hypothesized that men who were progressed to a higher risk disease 
would have lived less healthy lifestyles during the time they were managed with AS 
compared to those whose PCa has not yet progressed, suggesting that a healthy lifestyle 
may play a protective role in the progression of low- to intermediate-risk PCa.  
Methods 
Participants 
 The Research Ethics Board of Sunnybrook Health Sciences Centre in compliance 
with the Ontario Personal Health Information Act provided ethics approval. Informed 
consent was obtained from all participants. Recruitment of participants was accomplished 
by approaching patients with an intent to recruit those who came in to clinic for their 
regular scheduled appointments/visits during the period of recruitment for each cohort. All 
patients approached agreed to participate in the study. Between 2010 and 2011, 133 men 
diagnosed with low risk PCa and initially managed with AS were recruited from 
Sunnybrook Health Sciences Center. Two men were excluded from the study due to the fact 
that they opted for AS despite initial recommendation for treatment upon diagnosis. The 
remaining 131 participants were categorized into two groups: 1) those who were currently 
undergoing AS (“low risk”) and 2) those who were initially managed with AS but later 
reclassified to a higher risk of disease progression and subsequently underwent radical 
treatment (“progressed”). Moreover in 2013, 112 men diagnosed with low risk PCa and 
initially managed with AS were recruited from the Royal Marsden Hospital. One hundred 
and six men returned the questionnaire with sufficient data and were categorized into two 
groups: 1) those who had low- to intermediate-risk disease (“low risk”) and 2) those who 
initially presented with low risk disease but later reclassified to a higher risk of disease 
progression and/or underwent radical treatment (“progressed”). Categorizing men from 
the RMH cohort differently than those from the SB cohort was done in response to 
differences in available data. 
AS is a form of conservative management for men with “low risk” PCa, which 
according to the D’Amico definition involves Gleason score of ≤ 6 (3+3), a PSA of less than 
10 mg/ml, and a clinical stage of T1c or T2a. Some AS programs accept men with Gleason 7 
(4+3), provided they are older than 70 years and only have a small proportion of Gleason 4 
pattern [9]. Reclassification of patients to higher risk disease is triggered by the presence of 
Gleason pattern 4 or 5 on repeat biopsy or when extensive increases in volume of Gleason 
pattern 3 are found in patients under the age of 55, which warrants radical treatment [9]. 
Reclassification for men in the RMH cohort was similar; however in this study, the 
occurrence of adverse PSA kinetics (PSA doubling time of <3 years or a PSA velocity of >2.0 
per year) without a confirmed biopsy upgrade warranted reclassification, as adverse PSA 
kinetics have been shown to be a significant predictor of disease progression in this cohort 
[10].  
Lifestyle Assessment 
A modified version of the WHO STEPwise approach to chronic disease risk factor 
surveillance- Instrument version 3 [11] was used to obtain information on demographics, 
tobacco use, alcohol use, physical activity, dietary intake, medications and supplements, 
history of disease, and general health. Height, weight, and waist to hip circumference ratio 
were also measured. The survey was administered to men in the SB cohort through 
personal interviews and to men in the RMH cohort as a take home survey at various time 
points post-diagnosis. 
Indices were developed to assess each patient’s diet as a whole, as well as his fruit 
and vegetable intake. For the food groups that have been thought to promote PCa (milk 
products [12, 13], fast food, and red meat [14]), heavy, moderate and light consumption 
was given a score of 1, 2 and 3, respectively. For the food groups that have been reported to 
protect against PCa (fish [14], tomato products [14, 15], cruciferous vegetables [16], soy 
products [17], red grapes and/or red wine, and berries [18]), heavy, moderate, and light 
consumption were assigned a score of 3, 2, and 1, respectively. Raw scores for the overall 
dietary index (ranging from a minimum of 9 to a maximum of 27) were determined by 
calculating the total number of accrued points for all food groups, while the raw score for 
the fruits and vegetable index was equal to sum of the points accrued for regular 
consumption of tomato products, cruciferous vegetables, soy products, red grapes and/or 
red wine, and berries (min. 5, max. 15). Table I describes the interpretation of the raw 
scores for each index.  
Data regarding working/non-leisure, travel, and recreational physical activity was 
collected. Values of energy expenditure (metabolic equivalent task hours per week or MET-
hrs/week) for each activity were obtained from the Compendium of Physical Activities and 
adjusted according to body mass index and age with an equation established by Byrne et al 
[19]. Total, recreational and vigorous (activity requiring ≥6 MET-hrs) MET-hrs/week of 
physical activity was computed for each participant.  
 A lifestyle score was computed for each participant based on their total physical 
activity, dietary intake, body mass index, waist to hip circumference, tobacco use and 
alcohol use. Total MET hours/week of physical activity was split into quartiles per cohort 
and points were allotted to each participant according to their reported physical activity, 
with 0 points given to those in the least physically active quartile and 3 points given to 
those in the most physically active quartile. Diet scores were split into five levels (very 
poor, poor, average, good and excellent) and 0, 1, 2, 3, and 4 points were awarded 
accordingly. Participants were also awarded 1 point if they had a body mass index of less 
than 30 kg/m2, a waist to hip circumference ratio less than the median for each cohort, had 
never smoked or quit before their time on AS and had consumed less than 3 servings of 
alcohol daily. Increased physical activity was given a positive value, as previous research 
suggests a protective role with regard to PCa [7, 8, 20]. Body mass index [21, 22], waist to 
hip circumference ratio [23], tobacco use [24, 25] and alcohol use [26-28] provided 
negative contribution to the score, as they have been thought to promote PCa proliferation. 
Generalizing single unit values for each lifestyle factor and including multiple unit values 
with increased physical activity and diet quality was done in response to the lifestyle score 
developed by Kenfield et al (2015) [29]. In their study, an increased lifestyle score was 
associated with a reduced risk of lethal PCa. 
Statistical Analysis 
 All statistical analyses were done using IBM SPSS 22.0 (SPSS Inc., Chicago, IL). A 
sample size of 68 individuals per group was determined a priori to enable the detection of a 
moderately sized effect of d = 0.43, with a power of 0.8 and one-sided α of 0.05, reflecting 
differences between the two groups on lifestyle factors. Data were tested for normality 
using the Shapiro-Wilk test and equality of variance using Levene’s test. The two-tailed 
Student’s t-test was used to compare continuous data of normal distribution.  A one-sided 
Mann-Whitney U test was employed in the direction of the hypothesis to compare lifestyle 
scores while a two-sided Mann-Whitney U test was used to examine other non-parametric 
data. The chi-square or the Fisher’s exact test was used to establish whether categorical 
data were independent between groups. To determine whether any lifestyle variables were 
correlated to either total time to progression (treated and reclassified groups only), 
Pearson or Spearman correlation coefficients were used. Binary logistic regression 
analyses were performed for the lifestyle score, total MET-hrs/week, waist to hip 
circumference ratio, and overall dietary score adjusting for age at diagnosis and family 
history of PCa to determine the strength of predictability for progression to higher risk 
disease. Statistical significance for all analyses was denoted by a p-value <0.05. 
Results 
 Clinical and demographic data are summarized in Table II. Of the 131 men in the SB 
cohort, 76 (58%) remained low risk and 55 (42%) progressed and subsequently 
underwent radical treatment. Of the 106 men in the RMH cohort, 76 (71.7%) remained low 
risk and 30 (28.3%) progressed to higher risk disease, as indicated by clinical parameters, 
with 15 having undergone radical treatment at the time of recruitment. At the time of 
diagnosis, men in SB and RMH cohorts were on average younger in the low risk versus the 
progressed groups (63 (40-81) vs. 67 (48-79); p=0.0089 and 64.5 (51-78) vs. 68.5 (68-83); 
p=0.0051). This was also the case for age at the time of questionnaire completion (67 (45-
86) vs. 74 (48-89); p<0.0001 and 69.5 (53-83) vs. 71.5 (57-88); p=0.028). 
 The most common reasons for reclassification (or recommendation for definitive 
treatment) were Gleason score upgrade (31% and 37%), a combination of Gleason score 
upgrade and rising PSA values (20% and 3%), and abnormal PSA kinetics (27% and 47%). 
Three men (5%) from the SB cohort elected to undergo treatment due to cancer-related 
anxiety, despite showing no clinical signs of progression. Four men (13%) from the RMH 
cohort elected to undergo treatment for unknown reasons. However, patients from the 
RMH may have been recommended for treatment due to high PSA-density values (PSAD = 
0.161, 0.279, 0.327 and 0.328 ng/mL2). Although men from the low risk group remained on 
AS longer than men who progressed, total time on AS did not differ significantly between 
the comparative groups (p=0.62 and p=0.096). 
 There were no significant differences observed between groups with respect to 
baseline PSA values, body mass index, waist to hip circumference ratio, tobacco use, alcohol 
use, first-degree family history of PCa, and history of diabetes or cardiovascular 
disease/stroke. The majority of initial biopsies presented with Gleason 6 disease and a few 
with Gleason 7. Race distribution between groups was also similar. 
 Data regarding lifestyle characteristics and history of disease are summarized in 
Table III. In general, lifestyle scores were higher among men in the low risk compared to 
the progressed group in both cohorts (Figure 1). However, significance was only observed 
in the RMH cohort (p=0.046) and not in the SB cohort (p=0.14). On a binary logistic 
regression analysis, this difference was insignificant for both cohorts (95% CI = 0.77 to 
1.16; p=0.29 and 95% CI = 0.55 to 1.02; p=0.066) (Table IV).  
 Although insignificant, median levels of total and recreational physical activity were 
generally increased among men from the low risk compared to the progressed groups 
(Figure 2A & B). However, total physical activity was not predictive of progression on the 
binary logistic regression analysis when adjusting for age and other lifestyle variables 
(95% CI = 0.99 to 1.01; p=0.62 and 95% CI = 0.99 to 1.00; p=0.24) (Table V).  
 Significant differences in the overall dietary intake score and the fruits and 
vegetables intake score were not observed (Table III). Overall, the use of micronutrients 
and medications was not significantly different between comparative groups in both 
cohorts (data not shown). 
 Significant correlations were not observed between age at diagnosis, total MET 
hrs/week, diet score and fruit and vegetable intake score and total time to progression (if 
applicable) (Table V). A significant positive correlation of moderate strength was observed 
between age at the time of treatment and total time to progression on AS (r=0.36; p=0.0073 
and r=0.40; p=0.030) (Figure 3A & B). 
 All patients ranked their general health. On average, both groups reported “very 
good” physical and mental health and general quality of life. Overall pain and stress were 
ranked as “none”. Reported feelings of fatigue were increased among men in the 
progressed groups compared to the low risk group, although this was only significant in the 
RMH cohort (p=0.24 and p=0.010). 
Discussion  
Lifestyle characteristics were examined among patients in the SB cohort with 
comparisons made between men who remained on the AS protocol (low risk) and those 
who reclassified to a higher risk of disease progression and subsequently underwent 
radical treatment (progressed). Men who progressed were significantly older than men 
who remained low risk at the time of PCa diagnosis as well as at the time of questionnaire 
completion. However, the two groups did not significantly differ in total years on AS, which 
suggests that increasing length of time on surveillance was not the determining cause of 
reclassification. These findings are consistent with results from the RMH cohort, which 
compared lifestyle behaviors of men who remained low risk (low risk) and those who 
reclassified to a higher risk of disease progression (progressed) and/or underwent 
treatment. 
The primary objective was to investigate the role of lifestyle characteristics in 
protecting against progression of low- to intermediate-risk PCa in men on AS. Differences 
in lifestyle scores were modestly increased among men who remained low risk compared 
to those who progressed. One should note that this difference was only significant in the 
RMH cohort upon univariable analysis and borderline significant upon multivariable 
analysis. Using a similar scoring method, Kenfield et al (2015) demonstrated that a healthy 
lifestyle was associated with a reduced risk of lethal PCa among men from the Health 
Professionals Follow-up Study and men in the Physicians’ Health Study [29]. Moreover, 
improved lifestyle behaviors have demonstrated a protective role against the incidence of 
indolent and aggressive disease as well as biochemical recurrence [7, 8]. 
Of the lifestyle characteristics examined, only physical activity demonstrated a 
consistent difference between comparative groups upon univariable analysis. That is, 
median total and recreational physical activity were increased among men from the low 
risk compared to the progressed group in both cohorts. However, this difference was not 
significant upon univariable or multivariable analyses. 
Significant differences in the overall dietary index score and the fruits and 
vegetables index score were not observed between comparative groups in either cohort. 
This is inconsistent with previous studies that have demonstrated significant associations 
with dietary intake and PCa risk and progression [12, 14-17, 29]. The present study, 
however, collected information retrospectively, which negatively impacts recall when 
compared to prospective data collection. Moreover, the food frequency questionnaire used 
did not specify portion sizes for each serving. These limitations may explain the 
discrepancy in results with the previous studies, which collected data prospectively and 
included information on portion sizes [12, 14-17, 29]. Furthermore, despite the fact that 
the strength of each dietary factor’s role in PCa progression varies [18], equal weight was 
given to each dietary factor when calculating the index scores, likely leading to an over-
generalization of the impact of diet.  
 A significant positive correlation was observed in both cohorts between age at the 
time of reclassification and total time to progression. This is consistent with data from 
Tsodikov et al (2006) and Chefo & Tsodikov (2009) indicating an increased delay time with 
increase in age at diagnosis [30, 31]. It is thought that more aggressive disease stems from 
the increased genetic burden in early onset PCa [32] relative to PCa diagnosed in older 
men. This is supported by research demonstrating an association between early onset PCa 
and an increase in the number of risk alleles [33].  
 This study is limited by its retrospective nature and that lifestyle data was self-
reported and thus subject to the social desirability bias. Although consistent differences in 
lifestyle scores and physical activity were not significant upon multivariable analysis, the 
samples were small and may not have provided adequate power. As such, the occurrence of 
a type II error is possible. Moreover, there is a limited ability of self-report surveys to 
validly measure lifestyle behavior [34-36].  Future studies should consider the use of more 
objective measures in the assessment of lifestyle behaviors such as accelerometers or heart 
rate monitors to assess participation in physical activity and serum levels of nutrients 
indicative of dietary intake carotenoids, vitamin C and polyphenols to assess dietary intake 
[37, 38].  
Summary 
 A healthy lifestyle as defined by increased physical activity, good nutritional habits, 
a healthy body weight and composition, reduced alcohol consumption, and no tobacco 
consumption may help slow the progression of low risk PCa in patients initially managed 
with AS, thereby delaying their need for definitive treatment. In light of these results and 
the fact that leading a healthy lifestyle is safe and has well-known physiological benefits, 
men diagnosed with low- to intermediate-risk PCa and initially managed with AS should be 
advised to improve lifestyle habits. 
 Implications from the present study also suggest that the use of a lifestyle 
assessment questionnaire may aid in predicting the progression of low- to intermediate-
risk PCa in men enrolled in an AS program. Randomized control trials are warranted to 
more definitively determine the relationship between lifestyle characteristics and the 
progression of low- to intermediate-risk PCa.  
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 Figure 1. Comparison of the median and interquartile range of lifestyle scores between low 
risk and progressed groups from the Sunnybrook and Royal Marsden Hospital Cohorts. 
 
  
Figure 2. Comparison of the median and interquartile range of total physical activity (A) 
and recreational physical activity (B) in MET-hours/week performed by men in the low 
risk and progressed groups from the Sunnybrook cohort and Royal Marsden Hospital 
cohort. 
 
  
Figure 3. Correlation between age at the time of progression and total time to progression 
among men in the progressed group from the Sunnybrook cohort (A) and Royal Marsden 
Hospital (B) cohort.  
 
 
  
Table I. Interpretation of Overall Dietary and Fruits and Vegetables Indices 
 
Overall Dietary Index 
Fruits and Vegetables 
Index 
Raw Score Interpretation Raw Score Interpretation 
9-12 Very Poor   
13-16 Poor 5-8 Poor 
17-20 Average 9-12 Average 
21-24 Good 13-15 Good 
25-27 Very Good   
  
 
  
Table II. Clinical and demographic data for men from the Sunnybrook Cohort and the Royal 
Marsden Hospital Cohort 
 
Characteristic 
Sunnybrook 2011 Royal Marsden Hospital 2013 
Low Risk Progressed p-Value Low Risk Progressed p-Value 
Number of patients (%) 76  (58) 55  (42)  76 (71.7) 30 (28.3)  
Age at diagnosis, 
median (range) 
63 
(40-81) 
67 
(48-79) 
0.0089 
64.5 
(51-78) 
68.5 
(58-83) 
0.0051 
Age at questionnaire, 
median (range) 
67 
(45-86) 
74 
(48-89) 
<0.0001 
69.5 
(53-83) 
71.5 
(57-88) 
0.028 
Race, n (%)  
Caucasian 57 (75) 48 (87) 
 
72 (94.7) 27 (90) 
 
Black 11 (14) 4 (7) 1 (1.3) 0 (0) 
Other 8 (11) 3 (6) 2 (2.6) 2 (6.7) 
Unknown 0 (0) 0 (0) 1 (1.3) 1 (3.3) 
Time on surveillance, 
median (range) 
3.88 
(0.16-15.90) 
3.55 
(0.38-10.13) 
0.62 
4.80 
(0.6-10.7) 
2.25 
(0.6-10.5) 
0.096 
Baseline PSA, 
median (range) 
5.33 
(0.30-13.25) 
5.63 
(2.09-14.10) 
0.46 
6.25 
(0.9-26.6) 
6.17 
(1.5-21.0) 
0.51 
Body mass index, 
median (range) 
26.25 
(20.53-
26.01) 
26.63 
(20.37-
39.75) 
0.56 
27.20 
(20.2-40.8) 
27.95 
(22.2-39.4) 
0.29 
Gleason score at 
diagnosis, n (%) 
 
<6 0 (0) 1  (2) 
 
0 (0) 1 (3.3) 
 
6 (3+3) 71  (93) 46  (83) 73 (96.1) 28 (93.3) 
7 (3+4) 5  (7) 7  (13) 3 (3.9) 1 (3.3) 
Unknown 0 (0) 1 (2) 0 (0) 0 (0) 
Waist to hip ratio, 
median (range) 
0.98 
(0.87-1.13) 
0.97 
(0.81-1.12) 
0.35 
0.95 
(0.8-1.1) 
0.96 
(0.9-1.2) 
0.19 
 
 
 
  
Table III. Lifestyle characteristics and history of disease of men from the Sunnybrook 
Cohort and Royal Marsden Hospital Cohort 
 
  
 Sunnybrook 2011 Royal Marsden Hospital 2013 
Characteristic Low Risk Progressed p-Value Low Risk Progressed p-Value 
Lifestyle score,  
median (IQR) 
6 
(5-7) 
5 
(4-7) 
0.14 
6 
(5-7) 
5  
(4-7) 
0.046 
Vigorous PA, MET hrs/wk, 
median (IQR) 
24.90 
(4.47-52.72) 
26.95 
(0.00-57.57) 
0.79 
0 
(0-30.67) 
0 
(0-0) 
0.11 
Recreational PA, MET 
hrs/wk, median (IQR) 
49.34 
(23.60-63.48) 
35.43 
(20.09-65.03) 
0.18 
29.98 
(11.64–52.01) 
18.98 
(7.60–44.20) 
0.30 
Total PA, MET hrs/wk, 
median (IQR) 
78.79 
(48.36-105.66) 
51.30 
(34.31-95.41) 
0.11 
63.78 
(36.67-109.26) 
45.19 
(25.04-77.14) 
0.12 
Diet score, 
median (IQR) 
17 
(16-19) 
18 
(16-19) 
0.88 
15.5 
(14-17) 
15 
(13.25-17) 
0.68 
Fruit and vegetable 
intake score,  
median (IQR) 
10 
(8-11) 
9 
(8-10.5) 
0.59 
14 
(12-15) 
13.5 
(11.25-15) 
0.55 
Tobacco use, n (%)  0.47  0.37 
Heavy smoker 2  (3) 1  (2)  0  (0) 1  (3.3)  
Light smoker 3  (4) 0  (0) 2  (2.6) 2  (6.7) 
Former smoker 42  (55) 30  (54) 38  (50) 11  (36.7) 
Non-smoker 29  (38) 24  (44) 35  (46.1) 15  (50) 
Unknown 0  (0) 0  (0) 0  (0) 1  (3.3) 
Alcohol use, n (%)  0.45  0.86 
Heavy drinker 2  (3) 5  (9)  11  (14.5) 3  (10)  
Moderate drinker 23  (30) 15  (27) 16  (21.2) 7  (23.3) 
Light drinker 33  (43) 23  (42) 38  (50) 16  (53.3) 
Non-drinker 18  (24) 12  (22) 11  (14.5) 3  (10) 
Unknown 0  (0) 0  (0) 0  (0) 1  (3.3) 
Family history of Prostate 
Cancer, n (%) 
 
0.77 
 0.55 
Yes 15  (20) 12  (22)  12  (15.8) 7  (23.3) 
 No 61  (80) 43  (78) 52  (68.4) 20  (66.7) 
Unknown 0  (0) 0  (0) 12  (15.8) 3  (10) 
History of diabetes, n (%)  0.94  0.26 
Yes 10  (13) 7  (13)  6  (7.9) 3  (10) 
 No 66  (87) 48  (87)   70 (92.1) 26  (86.7) 
Unknown 0  (0) 0  (0) 0  (0) 1  (3.3) 
History of CVD/stroke, n (%)   0.40  0.24 
Yes 11  (14) 11  (20)  10  (13.2) 5  (16.7) 
 No 65  (86) 44  (80) 66  (86.8) 24  (80) 
Unknown 0  (0) 0  (0) 0  (0) 1  (3.3) 
Table IV. Results from the binary logistic regression analysis using lifestyle variables as 
predictors for progression 
 
 Sunnybrook 2011 Royal Marsden Hospital 2013 
Characteristic *Multivariable OR 
(95% CI) 
p-Value *Multivariable OR 
(95% CI) 
p-Value 
Age at diagnosis 1.06 
(1.01–1.11) 
0.014 
1.15 
(1.04–1.26) 
0.00067 
Family history of prostate 
cancer 
1.15 
(0.48-2.76) 
0.75 
1.56 
(0.49-4.93) 
0.45 
Lifestyle score 0.95 
(0.77-1.16) 
0.29 
0.75  
(0.55-1.02) 
0.066 
Total PA, MET hrs/wk 1.00 
(0.99-1.01) 
0.62 
1.00 
(0.99-1.00) 
0.24 
Diet score 0.99 
(0.86 – 1.14) 
0.88 
0.89 
(0.64-1.23) 
0.47 
Waist to hip ratio 0.029 
(0.000-10.85) 
0.24 
4111.70 
(0.35-4.88×105) 
0.082 
*Multivariable analysis for lifestyle score, physical activity, diet score and waist to hip ratio were adjusted for 
by age at diagnosis and family history of prostate cancer. Physical activity, diet score and waist to hip ratio 
were further adjusted by each lifestyle characteristic. 
 
  
Table V. Association between lifestyle variables and time to progression or treatment 
 
 Sunnybrook 2011 Royal Marsden Hospital 2013 
Characteristic Time to 
progression 
p-Value Time to 
progression 
p-Value 
Age at diagnosis, 
Pearson Coefficient (95% CI) 
-0.01 
(-0.27 to 0.21) 
0.95 
-0.039 
(-0.32 to 0.23) 
0.84 
Age at treatment, 
Pearson Coefficient (95% CI) 
0.36 
(0.12 to 0.53) 
0.0073 
0.40 
(0.10 to 0.61) 
0.030 
Total PA, MET hrs/wk,  
Spearman’s rho (95% CI) 
-0.11 
(-0.38 to 0.17) 
0.44 
-0.22 
(-0.57 to 0.18) 
0.24 
Diet score, 
Spearman’s rho (95% CI) 
0.15 
(-0.13 to 0.39) 
0.28 
0.074 
(-0.36 to 0.46) 
0.70 
Fruit and vegetable intake score, 
Pearson Coefficient (95% CI) 
0.17 
(-0.056 to 0.390) 
0.22 
-0.27 
(-0.59 to 0.078) 
0.15 
 
 
References 
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA 
Cancer J Clin. 2011;61:69-90. 
2. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress 
and promise. J Clin Oncol. 2011;29(27):3669-76. 
3. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local 
therapy among men with lower-risk prostate cancer in the United States. J Natl 
Cancer Inst. 2006;98:1134-41. 
4. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term 
follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin 
Oncol. 2015;33:272-7. 
5. Klotz, L. Active surveillance for low-risk prostate cancer. Curr Urol Rep. 
2015;16:492. 
6. Burton AJ, Martin RM, Donovan JL, Lane JA, Davis M, Hamdy FC, et al. Associations of 
lifestyle factors and anthropometric measures with repeat PSA levels during active 
surveillance/monitoring. Cancer Epidemiol Biomarkers Prev. 2012;21:1877-85. 
7. Frattaroli J, Weidner G, Dnistrian AM, Kemp C, Daubenmier JJ, Marlin RO, et al. 
Clinical events in prostate cancer lifestyle trial: results from two years of follow-up. 
Urology. 2008; 72:1319-23.  
8. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, et al. Intensive 
lifestyle changes may affect the progression of prostate cancer. J Urol. 
2005;174:1065-70. 
9. Klotz L. Active surveillance for prostate cancer: overview and update. Curr Treat 
Options Oncol. 2013;14:97-108. 
10. Ng MK, Van As N, Thomas K, Woode-Amissah R, Horwich A, Huddart R, et al. 
Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA 
velocity vs PSA doubling time. BJU Int. 2009;103:872-6. 
11. Bonita R, Decourten M, Dwyer T, Jamrozic K, Winkelmann R. Surveillance of risk 
factors for noncommunicable diseases: the WHO STEPwise approach. Geneva, 
Switzerland: World Health Organisation; 2002. 
12. Aune D, Navarro Rosenblatt DA, Chan DS, Vieira AR, Vieira R, Greenwood DC, et al. 
Dairy products, calcium, and prostate cancer risk: a systematic review and meta-
analysis of cohort studies. Am J Clin Nutr. 2015;101:87-117. 
13. Tate PL, Bibb R, Larcom LL. Milk stimulates growth of prostate cancer cells in 
culture. Nutr Cancer. 2011;63:1361-6. 
14. Chan JM, Holick CN, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, et al. Diet 
after diagnosis and the risk of prostate cancer progression, recurrence, and death 
(United States). Cancer Causes Control. 2006;17:199-208. 
15. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate 
cancer incidence and progression in the health professionals follow-up study. Int J 
Cancer. 2007;121:1571-8. 
16. Giovannucci E, Rimm EB, Stampfer MJ, Willett WC. A prospective study of 
cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev. 
2003;12:1403-9. 
17. Yan L, EL Spitznagel. Soy consumption and prostate cancer risk in men: a revisit of a 
meta-analysis. Am J Clin Nutr. 2009;89:1155-63. 
18. Richman, E.L., P.R. Carroll, and J.M. Chan, Vegetable and fruit intake after diagnosis 
and risk of prostate cancer progression. Int J Cancer. 2012;131:201-10. 
19. Byrne NM, Hills AP, Hunter GR, Weinsier RL, Shutz Y. Metabolic equivalent: one size 
does not fit all. J Appl Physiol. 2005;99:1112-9. 
20. Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical 
activity after diagnosis and risk of prostate cancer progression: data from the cancer 
of the prostate strategic urologic research endeavor. Cancer Res. 2011;71:3889-95. 
21. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the 
evidence. Eur Urol. 2013;63:800-9. 
22. Ploussard G, de la Taille A, Bayoud Y, Durand X, Terry S, Xylinas E, et al. The risk of 
upstaged disease increases with body mass index in low-risk prostate cancer 
patients eligible for active surveillance. Eur Urol, 2012;61:356-62. 
23. Su LJ, Arab L, Steck SE, Fontham ET, Schroeder JC, Bensen JT, et al. Obesity and 
prostate cancer aggressiveness among African and Caucasian Americans in a 
population-based study. Cancer Epidemiol Biomarkers Prev. 2011;20:844-53. 
24. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, et al. 
Cigarette smoking is associated with an increased risk of biochemical disease 
recurrence, metastasis, castration-resistant prostate cancer, and mortality after 
radical prostatectomy: results from the SEARCH database. Cancer. 2014;120:197-
204. 
25. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer 
survival and recurrence. Jama. 2011;305:2548-55. 
26. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V. Alcohol consumption 
and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J 
Cancer. 2015;112:580-93. 
27. McGregor SE, Courneya KS, Kopciuk KA, Tosevski C, Friedenreich CM. Case-control 
study of lifetime alcohol intake and prostate cancer risk. Cancer Causes Control. 
2013;24:451-61. 
28. Sawada M, Inoue M, Iwasaki M, Sasazuki S, Yamaji T, Shimazu T. Alcohol and 
smoking and subsequent risk of prostate cancer in Japanese men: the Japan Public 
Health Center-based prospective study. Int J Cancer. 2014;134:971-8. 
29. Kenfield SA, Batista JL, Jahn JL, Downer MK, Van Blarigan EL, Sesso HD, et al. 
Development and Application of a Lifestyle Score for Prevention of Lethal Prostate 
Cancer. J Natl Cancer Inst. 2015;108: pii: djv329. doi: 10.1093/jnci/djv329. Print 
2016 Mar. 
30. Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. 
Stat Med. 2006;25:2846-66. 
31. Chefo S, Tsodikov A. Stage-specific cancer incidence: an artificially mixed 
multinomial logit model. Stat Med. 2009;28:2054-76. 
32. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: 
an important clinical entity. Nat Rev Urol. 2014;11:317-23. 
33. Lindstrom S, Schumcher FR, Cox D, Travis RC, Albanes D, Allen NE, et al. Common 
genetic variants in prostate cancer risk prediction--results from the NCI Breast and 
Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 
2012;21:437-44. 
34. Prince SA, Adamo KB, Hamel ME, Hardt J, Connor Gorber S, Tremblay M. A 
comparison of direct versus self-report measures for assessing physical activity in 
adults: a systematic review. Int J Behav Nutr Phys Act. 2008;5:56. 
35. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. 
International physical activity questionnaire: 12-country reliability and validity. 
Med Sci Sports Exerc. 2003;35:1381-95. 
36. Cleland CL, Hunter RF, Kee F, Cupples ME, Sallis JF, Tully MA. Validity of the global 
physical activity questionnaire (GPAQ) in assessing levels and change in moderate-
vigorous physical activity and sedentary behaviour. BMC Public Health. 
2014;14:1255. 
37. Souverein OW, de Vries JH, Freese R, Watzi B, Bub A, Miller ER. Prediction of fruit 
and vegtable intake from biomarkers using individual participant data of diet-
controlled intervention studies. Br J Nutr. 2015;113:1396-409.  
38. Wang J, Tang L, Wang J-S. Biomarkers of Dietary Polyphenols in Cancer Studies: 
Current Evidence and Beyond. Oxidative Medicine and Cellular Longevity. 
2015;2015:732302. doi:10.1155/2015/732302. 
 
 
